Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Crosses Above 200 Day Moving Average - What's Next?

Key Points

• Cumberland Pharmaceuticals shares crossed above their 200-day moving average of $5.62, reaching $8.34 before closing at $7.94, although trading was reported down 3.2%.
• Despite the technical move, analyst sentiment remains negative: Weiss Ratings reiterated a “sell (D-)” rating, and the stock has an overall “Sell” consensus.
• The company reported weaker-than-expected quarterly results, with an adjusted loss of $0.20 per share versus the $0.13 expected and revenue of $0.17 million versus an $8.50 million consensus estimate.

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.62 and traded as high as $8.34. Cumberland Pharmaceuticals shares last traded at $7.94, with a volume of 76,217 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a report on Monday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of "Sell".

Cumberland Pharmaceuticals Trading Down 3.2%

The stock has a 50 day moving average of $7.34 and a 200-day moving average of $5.62. The stock has a market capitalization of $118.94 million, a P/E ratio of -11.18 and a beta of 0.13.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.07). Cumberland Pharmaceuticals had a negative net margin of 34.40% and a negative return on equity of 28.81%. The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $8.50 million.

Cumberland Pharmaceuticals Announces Dividend

The business also recently declared a dividend, which was paid on Friday, July 31st. Investors of record on Thursday, July 23rd were paid a $1.50 dividend.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Cumberland Pharmaceuticals during the second quarter worth approximately $412,000. Bank of New York Mellon Corp bought a new stake in shares of Cumberland Pharmaceuticals during the second quarter valued at approximately $379,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Cumberland Pharmaceuticals in the first quarter valued at approximately $66,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Cumberland Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 276,359 shares of the specialty pharmaceutical company's stock valued at $898,000 after purchasing an additional 4,081 shares during the period. 15.51% of the stock is currently owned by institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, acquisition and commercialization of prescription products for hospital care, gastroenterology and other targeted therapeutic areas. The company's business model emphasizes branded medicines that address specific clinical needs and are marketed primarily in the United States.

Its product portfolio has included Acetadote (acetylcysteine injection), used in the treatment of acetaminophen poisoning; Caldolor (ibuprofen injection), an intravenous nonsteroidal anti-inflammatory drug for pain and fever; and Kristalose (lactulose), a prescription treatment for constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.